Search results for "Plasmin"

showing 10 items of 176 documents

Genetic and environmental influences on the fibrinolytic system: a twin study.

2004

SummaryThe determination of heritability is a key issue to assess the predictive power of polymorphisms for disease in clinical studies. The aim of this study was to determine the heritability of proteins and activation markers of the fibrinolytic system in a large cohort of healthy twins. Heritability was calculated as 0.76 for thrombin activatable fibrinolysis inhibitor (TAFI), 0.44 for plasminogen activator inhibitor-1 (PAI-1), and 0.43 for tissue plasminogen activator. No significant genetic influence was observed for α2-antiplasmin-plasmin-complex and D-dimer. Heritability explained by single gene polymorphisms was 25.2% for TAFI 505G>A, 31.5% for 1542C>G, and 50.0% for combinati…

Malemedicine.medical_specialtyCarboxypeptidase B2GenotypeArteriosclerosismedicine.medical_treatmentBiologyEnvironmentTissue plasminogen activatorCohort StudiesFibrin Fibrinogen Degradation ProductsInternal medicineFibrinolysisPlasminogen Activator Inhibitor 1medicineDiseases in TwinsHumansFibrinolysinGeneGeneticsalpha-2-AntiplasminPolymorphism GeneticActivator (genetics)FibrinolysisHematologyTwins MonozygoticHeritabilityTwin studyEndocrinologyPhenotypeHaplotypesHemostasisTwin Studies as TopicFemalePlasminogen activatormedicine.drugThrombosis and haemostasis
researchProduct

Massive pulmonary embolism in a young boy with T-cell leukaemia. Successful thrombolytic therapy by recombinant tissue plasminogen activator (rtPA).

2014

SummaryAcute pulmonary embolism (PE) is a serious complication in association with malignant diseases. We describe the successful treatment of PE applying a systemic thrombolytic therapy in a 4-year-old boy with acute lymphoblastic leukaemia.The thrombolytic therapy with recombinant tissue plasminogen activator (rtPA) 0.1 mg/ kg bodyweight per hour for six hours was continued for six days without important side effects. In particular no bleeding complications were observed. Computed tomography with contrast revealed a remarkable regression of the central PE. Without further delays the chemotherapy was resumed.

Malemedicine.medical_specialtyLeukemia T-Cellmedicine.medical_treatmentComputed tomographyFibrinolytic AgentsmedicineHumansRecombinant tissue plasminogen activatorChemotherapymedicine.diagnostic_testbusiness.industryAnticoagulantsHematologyHeparin Low-Molecular-Weightmedicine.diseaseRecombinant ProteinsSurgeryPulmonary embolismTreatment OutcomeChild PreschoolTissue Plasminogen ActivatorLymphoblastic leukaemiaDrug Therapy CombinationbusinessComplicationPulmonary EmbolismT cell leukaemiaHamostaseologie
researchProduct

Urokinase-plasminogen-activator receptor expression in disseminated tumour cells in the bone marrow and peripheral blood of patients with clinically …

2009

OBJECTIVE To evaluate the expression of urokinase-plasminogen-activator receptor (uPA-R) in disseminated tumour cells (DTC) in bone marrow (BM) and peripheral blood (PB) of patients with clinically localized prostate cancer before radical prostatectomy (RP), and to assess the associations with pathological variables and prognosis. PATIENTS AND METHODS In all, 52 patients (47 with clinically localized cancer and five with benign prostatic hyperplasia, BPH, as controls) were prospectively enrolled. BM and PB samples were drawn before surgery. DTC were enriched using a commercial system, cytokeratin (CK) 8/18 was used to detect DTC, and uPA-R expression was detected by dual-immunostaining of t…

Malemedicine.medical_specialtyPathologyUrologyReceptor expressionmedicine.medical_treatmentGastroenterologyReceptors Urokinase Plasminogen ActivatorCytokeratinProstate cancerBone MarrowInternal medicinemedicineBiomarkers TumorHumansAgedProstatectomybusiness.industryProstatectomyCancerProstatic NeoplasmsHyperplasiaMiddle AgedProstate-Specific Antigenmedicine.diseaseNeoplastic Cells CirculatingPrognosisImmunohistochemistryUrokinase receptormedicine.anatomical_structureLymphatic MetastasisBone marrowNeoplasm Recurrence LocalbusinessEpidemiologic MethodsBJU international
researchProduct

Time Trends in Hospital-Referred Stroke and Transient Ischemic Attack: Results of a 7-Year Nationwide Survey in France

2010

<i>Background:</i> Nationwide evaluations of the burden of stroke are scarce. We aimed to evaluate trends in stroke and transient ischemic attack (TIA) hospitalization, in-hospital case fatality rates (CFRs) and mortality rates in France during 2000–2006. <i>Methods:</i> Hospitalizations for stroke and TIA were determined from National Hospital Discharge Diagnosis Records that used the International Classification of Disease, 10th revision, codes I60, I61, I63, I64, G45, G46. CFRs and mortality rates were estimated from the national death certificates database. <i>Results:</i> The total number of stays for stroke increased between 2000 and 2006 (88,371 vs…

Malemedicine.medical_specialtyPediatrics030204 cardiovascular system & hematologyStroke mortalityNationwide survey03 medical and health sciences0302 clinical medicineHealth care policyEpidemiologymedicineHumansOrganized stroke careLongitudinal Studiescardiovascular diseasesTransient ischemic attackStrokeAgedRetrospective StudiesAged 80 and overHospital stayIn hospital mortalityStroke epidemiologyTime trendsbusiness.industryRetrospective cohort studyLength of Staymedicine.diseaseHealth Surveysnervous system diseases3. Good healthHospitalizationSurvival RateStrokeIn-hospital mortalityNeurologyIschemic Attack TransientTissue Plasminogen ActivatorIncidence and mortality ratesFemale[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieNeurology (clinical)FranceCardiology and Cardiovascular MedicinebusinessHospital stay030217 neurology & neurosurgery
researchProduct

Immune-inflammatory markers and arterial stiffness indexes in subjects with acute ischemic stroke.

2010

Abstract No study has yet evaluated the relationship between arterial stiffness indexes and immuno-inflammatory pathway in patients with an acute cardiovascular or cerebrovascular event. The aim of our study was to evaluate in patients with acute ischemic stroke the relationship between immune-inflammatory markers and arterial stiffness indexes. Methods 107 subjects with acute ischemic stroke and 107 controls without stroke. We evaluated plasma levels of C-reactive protein (CRP), interleukin-1beta (IL-1β), tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6) and interleukin-10 (IL-10), E-selectin, P-selectin, intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1…

Malemedicine.medical_specialtySettore MED/09 - Medicina InternaEmbolismTissue plasminogen activatorVon Willebrand factorIschemiaInternal medicinevon Willebrand FactormedicineHumanscardiovascular diseasesStrokePulse wave velocityAgedAged 80 and overInflammationbiologybusiness.industryCerebral infarctionMiddle Agedmedicine.diseaseAtherosclerosisischemic stroke arterial stiffnessSurgeryStrokeCarotid ArteriesImmune SystemAcute Diseasecardiovascular systemArterial stiffnessCardiologybiology.proteinCytokinesAortic stiffnessFemaleCardiology and Cardiovascular MedicinebusinessPlasminogen activatorcirculatory and respiratory physiologymedicine.drugAtherosclerosis
researchProduct

Thrombolysis with saruplase versus streptokinase in acute myocardial infarction: five-year results of the PRIMI trial.

1999

Abstract Background Short-term safety and efficacy of thrombolysis with saruplase in acute myocardial infarction have been shown in several trials. To assess long-term outcome of patients treated with saruplase or streptokinase for myocardial infarction, a 5-year follow-up of patients included in the Pro-Urokinase in Myocardial Infarction Trial was performed. Methods and Results Follow-up data are available from 8 centers on 255 (92.4%) of 276 included patients. The 5-year mortality rate was comparable with 20.8% of patients in the saruplase group and 16.9% in the streptokinase group (odds ratio 1.29, 95% confidence interval 0.69 to 2.42). In both groups, a considerable number of fatal card…

Malemedicine.medical_specialtyStreptokinasemedicine.medical_treatmentMyocardial InfarctionAnginaCohort StudiesFibrinolytic AgentsRecurrenceAngioplastyInternal medicineMedicineHumansStreptokinaseThrombolytic TherapyMyocardial infarctionAngioplasty Balloon CoronaryCoronary Artery BypassAgedbusiness.industryOdds ratioThrombolysisMiddle Agedmedicine.diseaseSurvival AnalysisUrokinase-Type Plasminogen ActivatorConfidence intervalRecombinant ProteinsCerebrovascular DisordersCardiologySaruplaseFemaleCardiology and Cardiovascular Medicinebusinessmedicine.drugFollow-Up StudiesAmerican heart journal
researchProduct

Is delayed facilitated percutaneous coronary intervention better than immediate in reperfused myocardial infarction? Six months follow up findings

2006

Background: There are several new strategies proposed to improve the outcome of patients with ST-elevation myocardial infarction (STEMI). One approach is the resurgent use of facilitated percutaneous coronary interventions (PCI). Until recently, deciding whether immediate PCI after combined treatment (facilitated PCI) is more appropriate than delayed PCI (short time) has not been investigated. The aim of this study, therefore, was to investigate the outcomes in patients initially successfully treated pharmacologically and immediate PCI < 2 hr, and in patients initially successfully treated with pharmacological therapy and with delayed PCI (12–72 h). Methods: 451 reperfused STEMI patients, a…

Malemedicine.medical_specialtyTiclopidineTime Factorsmedicine.medical_treatmentMyocardial InfarctionFacilitated Percutaneous Coronary InterventionPlatelet Glycoprotein GPIIb-IIIa ComplexGIIb/IIIa inhibitorDelayed Percutaneous Coronary InterventionsInternal medicineAngioplastymedicineAbciximabAcute myocardial InfarctionHumanscardiovascular diseasesMyocardial infarctionAngioplasty Balloon CoronaryAgedbusiness.industryAnticoagulantsPercutaneous coronary interventionHematologyTirofibanMiddle AgedClopidogrelmedicine.diseaseCombined Modality TherapyClopidogrelsurgical procedures operativeTissue Plasminogen ActivatorConventional PCICardiologyFemaleCardiology and Cardiovascular MedicinebusinesstherapeuticsCombined therapyPlatelet Aggregation InhibitorsTIMIFollow-Up Studiesmedicine.drugJournal of Thrombosis and Thrombolysis
researchProduct

Cardio‐Renal Biomarker Soluble Urokinase‐Type Plasminogen Activator Receptor Is Associated With Cardiovascular Death and Myocardial Infarction in Pat…

2020

Background Risk stratification among patients with coronary artery disease ( CAD ) is of considerable interest due to the potential to guide secondary preventive therapies. Thus, we evaluated the predictive value of soluble urokinase‐type plasminogen activator receptor (su PAR ) levels for cardiovascular mortality and nonfatal myocardial infarction in patients with CAD . Methods and Results Plasma levels of su PAR were measured in a cohort of 1703 patients with documented CAD as evidenced by coronary angiography—including 626 patients with acute coronary syndrome and 1077 patients with stable angina pectoris. Cardiovascular death and/or nonfatal myocardial infarction were defined as main o…

Malemedicine.medical_specialtyTime FactorsEpidemiologyMyocardial InfarctionRenal functionCoronary Artery Disease030204 cardiovascular system & hematologyKidneyRisk AssessmentReceptors Urokinase Plasminogen Activatorsoluble urokinase‐type plasminogen activator receptorTroponin CCoronary artery disease03 medical and health sciences0302 clinical medicinePredictive Value of TestsRisk FactorsGermanyInternal medicineSecondary PreventionmedicineHumanscardiovascular diseasesMyocardial infarctionReceptorAgedOriginal Research030304 developmental biologyUrokinase0303 health sciencesbusiness.industryMiddle AgedPrognosismedicine.diseaseTroponinC-Reactive ProteinHeart Disease Risk FactorsCardiologybiomarkerBiomarker (medicine)FemaleKidney DiseasesCardiology and Cardiovascular MedicinebusinessPlasminogen activatorBiomarkersGlomerular Filtration Ratemedicine.drugJournal of the American Heart Association
researchProduct

Immunoinflammatory activation during the acute phase of lacunar and non-lacunar ischemic stroke: Association with time of onset and diabetic state

2006

Several studies have stressed the involvement of inflammation in the pathophysiology of acute brain ischemia, but the role of immunoinflammatory activation in diabetic stroke patients has not yet been fully evaluated. The aim of our study was to evaluate immunoinflammatory activation of acute phase of stroke in relation to time of symptoms onset, diabetic state and diagnostic subtype. We enrolled 60 patients (32 diabetics; 28 non- diabetics) with acute ischemic stroke and 123 subjects without acute ischemic stroke, and measured levels of IL-1β, TNF-α, IL-6, IL-10, E-selectin, P-selectin, sICAM-1, sVCAM-1, VWF, 24–72 h and 7–10 days after stroke onset; TPA, PAI-1 plasma levels at 24–72h. Ou…

Malemedicine.medical_specialtyTime FactorsImmunologyInflammationDiseaseBrain IschemiaBrain ischemia03 medical and health scienceschemistry.chemical_compound0302 clinical medicinestroke diabetes mellitusInternal medicineDiabetes mellitusPlasminogen Activator Inhibitor 1medicineDiabetes MellitusImmunology and AllergyHumanscardiovascular diseasesStrokeAgedPharmacologyAged 80 and overInflammationbusiness.industryTumor Necrosis Factor-alphaMiddle Agedmedicine.diseaseIntercellular Adhesion Molecule-1PathophysiologyStrokechemistry030220 oncology & carcinogenesisPlasminogen activator inhibitor-1Acute DiseaseCardiologyFemalemedicine.symptombusinessSelectin030215 immunologyInterleukin-1
researchProduct

Safety and tolerability of abciximab in patients with acute myocardial infarction and failed thrombolysis.

2003

Abstract Aim: The aim of this study was to evaluate glycoprotein IIb/IIIa receptor inhibitor effectiveness in AMI patients with unsuccessful thrombolysis. Methods: Eighty-four patients hospitalised within 4 h of symptom onset were randomised (single blind) into two groups. Regardless of the group, placebo or GP IIb/IIIa inhibitors were administered to patients who did not present with reperfusion signs 30 min after starting thrombolysis and 30–60 min after the end of full thrombolysis in patients with pain recurrence and ST-segment elevation. Reperfusion was assessed by the creatine kinase peak occurring within 12 h, by the observation of rapid ST-segment reduction (50–70% within 1 h) in 12…

Malemedicine.medical_specialtyTime Factorsmedicine.medical_treatmentAbciximabMyocardial InfarctionMyocardial ReperfusionPlatelet Glycoprotein GPIIb-IIIa ComplexPlaceboCoronary AngiographyAnginaElectrocardiographyImmunoglobulin Fab FragmentsInternal medicineFibrinolysisAbciximabmedicineHumansSingle-Blind MethodThrombolytic TherapyMyocardial infarctionTreatment FailureAngioplasty Balloon CoronaryAspirinbusiness.industryAntibodies MonoclonalThrombolysisMiddle Agedmedicine.diseaseTolerabilityResearch DesignAnesthesiaTissue Plasminogen ActivatorCardiologyFemaleSafetyCardiology and Cardiovascular MedicinebusinessPlatelet Aggregation Inhibitorsmedicine.drugInternational journal of cardiology
researchProduct